Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating income | -$1.03M | -$2.23M | -$2.37M | -$2.31M | -$2.09M | -$2.55M | -$4.14M | -$3.56M | -$4.53M | -$5.70M |
| Net income | -$1.02M | -$2.28M | -$2.26M | -$2.56M | -$1.75M | -$2.55M | -$4.52M | -$3.56M | -$5.00M | -$5.53M |
| EPS (diluted) | -$0.15 | -$0.43 | -$0.22 | -$0.25 | -$0.17 | -$0.25 | -$0.31 | -$0.82 | -$1.15 | -$1.13 |
| Fiscal year | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$381K | -$1.14M | -$1.38M | -$1.07M | -$488K | -$1.35M | -$2.80M | -$1.99M | -$3.70M | -$4.22M |
| Capital expenditures | $1.79K | — | — | — | — | — | — | $1.80K | $150K | — |
| Free cash flow | -$383K | — | — | — | — | — | — | -$2.00M | -$3.85M | — |
| Fiscal year | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $3.34K | $3.10M | $400K | $362K | $799K | $671K | — | — | — | — |
| Total assets | $11.1K | $3.16M | $1.78M | $697K | $842K | $879K | $11.1M | $8.04M | $4.32M | $1.96M |
| Total liabilities | $704K | — | — | $908K | $1.48M | $2.03M | $1.12M | $1.12M | $655K | $943K |
| Shareholders' equity | -$667K | $2.48M | $1.22M | -$211K | -$634K | -$1.15M | $9.94M | $6.92M | $3.67M | $1.01M |
| Retained earnings | -$6.31M | -$8.58M | -$10.8M | -$13.4M | -$15.2M | -$17.7M | -$22.2M | -$25.8M | -$30.8M | -$36.3M |
| Shares (wtd avg diluted) | 6.61M | 10.3M | 10.3M | 10.3M | 10.3M | 10.4M | 3.69M | 4.32M | 4.34M | 4.90M |
Every figure is extracted from Protagenic Therapeutics, Inc.\new’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.